Skip to main content
Download PDF

Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study

BMC Nephrology volume 26, Article number: 197 (2025) Cite this article

Abstract

Background

Chronic kidney disease (CKD) patients are prone to osteoporosis (OP) and they had significant oxidative stress. The relationship between oxidative stress (OS) and bone mineral density (BMD) in CKD is not entirely clear. The investigation of this relation is of pronounced importance in decreasing the occurrence of osteoporosis among CKD cases.

Objectives

To evaluate the association between BMD and OS in CKD patients.

Methods

We performed a case-control study, including 150 adults with CKD (stage 1–5 according to Kidney Disease Improving Global Outcomes (KDIGO) classification, 2024) and 150 healthy controls. CKD patients were further subdivided to 3 subgroups based on estimated glomerular filtration rate: stage 1–2, stage 3–4 and stage 5. BMD at the lumbar spine (LS), femur neck (FN), and distal radius (DR) were measured using DEXA. Vitamin D and OS biomarkers including; 8-Hydroxy-2’-deoxyguanosine (8-OHdG) and Malondialdehyde (MDA) were measured. Paraoxonase1 (PON1) as a biomarker of antioxidant response was assessed. Statistical analysis was performed using the appropriate tests.

Results

The CKD cases showed lower BMD T-Scores than healthy controls. Moreover, LS, DR, and FN BMDs were significantly different between CKD stages. Post hoc analyses showed higher LS, DR, and FN T-Scores in Stage I-II vs. Stage III-IV and Stage V. However, no significant differences were noted between stage III-IV and stage V for all sites. Significant increase in OS biomarkers (8-OHdG and MDA) while decreasing antioxidant activity (PON-1) with CKD severity were observed. There was a significant positive correlation between PON1and BMD while 8-OHdG and MDA had a negative correlation with BMD. We also observed significant positive correlations between 8-OHdG and MDA with alkaline phosphatase and phosphorus, while these markers had significant negative correlations with vitamin D and calcium. PON1 had a significantly positive correlation with vitamin D & calcium.

Conclusion

CKD patients suffer of OS. OS positively correlated with CKD severity. There is a negative relation between OS and BMD in CKD. OS might participate in the occurrence of OP in CKD.

Peer Review reports

Background

Chronic kidney disease (CKD) is a general worldwide health problem [1]. CKD is defined by KIDIGO, 2024 as abnormalities of kidney structure or function, present for a minimum of 3 months, with implications for health. CKD is classified based on cause, glomerular filtration rate (GFR) category (G1–G5), and albuminuria category (A1–A3), abbreviated as CGA [2]. Bone fractures are common in patients with CKD [3].

CKD is associated with the development of mineral bone disorder (MBD), OP, and fragility fractures [4]. CKD-related OP is a major complication in patients with CKD, conferring a higher risk of adverse outcomes [5]. Fractures were reported to be greater than 2 to 100-fold more common in CKD than in age-matched individuals without CKD [6,7,8].

Data from the National Health And Nutrition Examination Survey (NHANES) suggested that CKD and OP are highly co-prevalent [7, 9]. Therefore, Moe suggested that the term CKD-induced OP [10]. OP was two-fold as present in cases having eGFR < 60 mL/min than cases having eGFR > 60 mL/min amongst the NHANES III contributors [7].

OP is a global disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk [11, 12]. According to the National Institutes of Health Consensus Development Panel on Osteoporosis, OP is defined as a skeletal disorder characterized by compromised bone strength leading to an increased risk of fracture [13].

Moreover, according to the World Health Organization (WHO) criteria, OP is defined on the basis of T-score which is BMD ≥ 2.5 SDs below young adult mean. This definition of OP is for postmenopausal women and men above 50 years. It has to be mentioned that WHO criteria must not be used for men below 50 years, pediatric population, or premenopausal females. For those individuals, the International Society for Clinical Densitometry (ISCD) endorses applying the Z score (age and sex norms). Z scores ≤ − 2.0 are below the expected range for age and a secondary causes of OP should be searched for [14].

OS is the disturbance between oxidants and antioxidants towards increase in oxidants, causing a disturbance of redox signaling and/or injury of the molecules [15]. It is well-recognized that OS participates in CKD pathogenesis. It has been linked to OP also [16]. Disturbances in cell management of oxidants affects renal cell signaling, endorsing apoptosis and senility of kidney cells and reducing the capability of cells to regenerate. Thus, affecting renal function deleteriously [17].

The primary endogenous systems involved in the synthesis of oxidants comprising reactive oxygen species (ROS) like hydrogen peroxide (H2O2) and superoxide anion (O2•−) during normal metabolism is NADPH oxidase. Efficient antioxidant systems, such as vitamins E and C, glutathione peroxidase, reduced glutathione, superoxide dismutase, paraoxonase, and catalase, often balance out this creation of ROS under healthy conditions [18].

When the intracellular production of ROS is controlled, they act as second messengers by regulating and activating signaling transduction pathways involved in numerous biological processes such as apoptosis, survival, differentiation, proliferation, and inflammation [19]. Bone repair and bone remodeling are also redox -regulated processes, and the physiological redox state is essential for the equilibrium between osteoblastogenesis and osteoclastogenesis [20].

OS impairs mitochondrial function in osteoblasts, reducing ALP expression, activity, and mineralization capacity [21]. It promotes osteoclasts formation and differentiation. Studies showed that ROS can directly or indirectly stimulate osteoclast differentiation, augmenting their activity and numbers. The transient production of ROS due to transformation of receptor activator of nuclear kB ligand (RANKL) into osteoclastic precursor is very important for its role in the induction of osteoclastogenesis, and this indicates that ROS act as intracellular mediators for osteoclastic differentiation. This is through RANKL activation of the differentiation and activity of osteoclasts by interacting with specific receptors in pre-ostoeclasts and mediates osteoclastogenesis and bone resorption [21]. Moreover, H2O2 increases TRAP expression and upregulates RANKL expression, promoting osteoclast differentiation and activity [22].

Thus, OS has the ability to change the equilibrium between osteobalstogenesis and osteoclastogenesis. OP results from this change because it reduces bone mass. Specifically, increased ROS generation decreases osteoblastogenesis and osteoblastic activity while increasing osteoclastogenesis [23].

However, conflicting results about the association between BMD and OS in CKD have been reported. We hypothesized that the OS state in CKD patients plays a role in the associated reduction of BMD. Consequently, we carried out our study to assess the relation between BMD and OS in CKD patients.

Methods

Sample size calculation

Setting the power = 0.80 and α = 0.05 with using PASS 11th release [24], a minimal sample size of 99 cases was required to get statistical significance between null value of correlation coefficient (0.000) and assumed correlation coefficient (0.278) between T-scores at the spine correlated with phosphate in cases with CKD [25]. We included 150 cases with CKD and equal number (150) of healthy control subjects.

Ethical approval

The study was approved by the Ethical Committee of Al-Azhar University (No. 1758) according to the World Medical Association’s Declaration of Helsinki. Written informed consent was obtained from patients after explaining the study for them.

Type of the study, settings and participants

We conducted a case-control, cross sectional study, including 150 adults attending the Nephrology Clinic of Alzahraa University Hospital with CKD not receiving hemodialysis (stage 1–5 according to KDIGO, 2024 [2]) and 150 normal healthy volunteers, as controls. Controls had no complaints, history of chronic disease, or abnormal clinical examination findings. CKD patients were subdivided to three groups according to estimated glomerular filtration rate (eGFR); stage 1–2, stage 3–4 and stage 5, none of our patients was on hemodialysis.

Stage 1 CKD was defined as cases with eGFR ≥ 90 mL/min/1.73m2, stage 2 CKD as eGFR 60 to 89 mL/min/1.73m2, stage 3 CKD as eGFR 30 to 59 mL/min/1.73 m2, stage 4 as those with eGFR 15–29 mL/min/1.73m2, and stage 5 as those with eGFR < 15 mL/min/1.73m2. For eGFR calculation, we adopted the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [26].

Exclusion criteria

  • Pregnant, breastfeeding females as hormonal changes can significantly affect bone metabolism.

  • Individuals with excessive alcohol consumption as well as tobacco smokers were excluded from the study.

  • Patients with acute inflammation, active infection, malignant diseases, metabolic, congenital bone disease or previous lumbar vertebrae surgery, patients who are frequently exposed to ionizing radiation or regularly use drugs lead to osteoporosis like corticosteroids or those regularly use drugs treating osteoporosis (e.g. teriparatide, bisphosphonates & estrogen).

Procedures

I-Clinical evaluation

The following was done for all included individuals:

  • History taking and thorough clinical examination.

  • Anthropometric assessment including; body weight to the nearest 0.1 kg and height to the nearest 0.1 cm were taken according to the instructions of International Biological Program [27]. Body mass index (BMI) was calculated according to the equation; weight (Kg) / height (meter2).

II-Evaluation of BMD

For OP identification, dual-energy X-ray absorptiometry (DEXA) is the corner stone. The principle of its action is as follows; when X-rays move throughout bodily tissues, their strength is weakened to varying degrees inside various types of tissues. It uses X-rays at two energy levels. The best beneficial sites are the lumbar vertebrae and neck of femur [28]. In the current study we measured BMD at three sites; femoral neck, lumbar spine and distal radius as they represent the BMD for the bones of the body in general and not only specific bones. Clinically, BMD is usually used to diagnose OP. Cancellous bone (60–75%) in the total skeletal system is concentrated in the lumbar spine, thus the initial alterations in bone mineral content can be reflected by assessment of lumbar BMD in CKD cases. Moreover, the rate of bone turnover in cancellous bone is greater than that of cortical bone and it is more sensitive to metabolic stimuli. Additionally, its accumulation of bone mass will reach the topmost before the cortical bone, hence the assessment of lateral lumbar BMD is having greater sensitivity [29].

In addition, the femoral neck, lumbar spine and distal radius are part of the standardized protocol recommended by the WHO and the International Society for Clinical Densitometry (ISCD) to measure the BMD of the body bones. These sites are chosen because they are the most predictive of fracture risk and are widely accepted in clinical practice world-wide [30]. DEXA was done using GE Healthcare Care lunar IDXA with central scan device.

a-Appropriate patient positioning

It is significant for the patient to be put in the right position to get a better evaluation of BMD for diagnosing OP. During lumbar spine and femoral neck measurement, the patient should be placed in a supine position and when it comes for imaging of the forearm he should sit next to the table. In proximal femur scans requires the patient to rotate the foot internally so as the femoral neck will be parallel to the table and the lesser trochanter will be hidden as much as he can. improper patient positioning can cause under- or over-estimation of BMD [31].

b-BMD interpretation

BMD should be expressed as raw values (g/cm2) as well as T scores. However, in clinical practice, raw BMD values (g/cm2) are not normally used for assessing skeletal status and fracture risk. Instead, the BMD values are expressed in terms of the number of standard deviations above or below the young normal value (commonly referred to as the T-score) [32].

According to the WHO, OP was diagnosed in cases with BMD T score less than or equal to − 2.5, while osteopenia was diagnosed with T score between − 1 and − 2.5 and normal BMD was considered if T score higher than − 1 [33].

III-Laboratory investigations

5 ml venous blood were taken while fasting, and put in plain tubes, left to clot then centrifuged and serum was separated and kept at -80 C till analysed to assess:

  1. 1.

    Serum creatinine, albumin, calcium, phosphorous, and alkaline phosphatase using the Hitachi 704 Auto-analyzer and colorimetric enzymatic techniques (Roche Diagnostics. Switzerland).

  2. 2.

    Measurement of OS biomarkers:

    1. a.

      Lipid peroxidation (MDA) assay: Using Nair and Turne’s approach [34], Malondialdehyde (MDA), a byproduct of lipid peroxidation, was measured in serum. That assessment produces the TBA-MDA adduct, that could be detected colorimetrically at 532 nm, when thiobarbituric acid and thiobarbituric acid reactive substances (TBARS) react.

    2. b.

      Estimation of 8-Hydroxy-2’-deoxyguanosine (8-OHdG) serum levels: Using ELISA kits, serum concentrations of 8-OHdG were measured twice according to Sinogene Clon Biotech Co. Catalog No. SL- 2044 Hu.

  3. 3.

    Assessment of serum Paraoxonase-1 (PON-1) as an antioxidant: Phenyl acetate was used as a substrate in a colorimetric technique to measure PON-1’s arylesterase activity. PON-1 catalyses the cleavage of phenyl acetate, which forms phenol. The increase in absorbance at 270 nm at 25 °C was used to calculate the rate at which phenol was forming. The working mixture included 4 mM phenyl acetate as the substrate and 20 mM Tris/HCl buffer, pH 8.0, with 1 mM CaCl2. After adding samples diluted 1:3 in buffer to the mixture above, a 20-second lag time was used to record the changes in absorbance. One µmole of phenol generated per minute is equivalent to one unit of arylesterase activity. Based on phenol’s 1310 M‒1 cm‒1 extinction coefficient, PON1 activity was represented in kU/L. Water-containing blank samples were utilized to account for phenyl acetate’s spontaneous hydrolysis [35].

  4. 4.

    Estimation of 25- OH vit D3 serum levels: Vitamin D direct ELISA Kit (EIA-4696) (DRG ® International, Inc. USA) was used to measure serum 25 hydroxy vitamin D (25 (OH) vit D3).

  5. 5.

    Estimation of PTH levels: PTH was measured using the enzyme-linked immune-sorbent assay (ELISA) in line with ELK Biotech Co. Catalog No. ELK2427.

IV-Statistical analysis

Data were analyzed using SPSS version 20.0 (Statistical SPSS Inc, Chicago, IL, USA). The normality of the data was examined using the Shapiro-Wilk test. Non-parametric statistics were demonstrated as median (minimum-maximum) and IQR, but parametric variables were demonstrated as mean ± SD. Participant characteristics were first compared between CKD and the control group using Student’s t-test, for normally distributed data while Mann-Whitney U test was used for non-parametric data. One-way analysis of variance (ANOVA) was used to compare between means of the studied subgroups at different CKD stages followed by independent-sample t-test for subgroups with normally distributed data using post-hoc analysis while Kruskal-Wallis test was used for non-parametric data followed by Mann- Whitney U test. Qualitative data were described as number and percentage and compared using Chi square test and Fisher’s Exact test for variables with small expected numbers. Correlation between BMD and OS biomarkers was done using Pearson correlation coefficient test. Multiple regression analysis of both BMD and OS variables was assessed. P-values below 0.05 were considered significant in all analyses.

Results

Table 1 shows comparison of demographic data and anthropometric measures between the controls and total CKD patients (P1). The different stages of CKD were compared together (P2). Neither age, weight, sex distribution nor BMI differed significantly (p > 0.05) between the total CKD patients and the controls or between the three subgroups of CKD.

Table 1 Demographic data and anthropometric measurements of the total CKD patients and subgroups
Full size table

Regarding the clinical data of our cases, there were no significant difference between the studied groups, (p > 0.05) for all as shown in Table 2.

Table 2 Clinical data of the studied groups
Full size table

Table 3 shows comparison of BMD T-scores among the studied groups. Total CKD patients had lower T-scores for LS, DR and FN compared to healthy control group (p = 0.001), whereas cases with StageI-II had higher T-scores compared to Stage III-IV and Stage V (p < 0.05), patients with advanced CKD had lower T-scores based on ANOVA and post hoc test. While no significant difference was found for all T-scores between Stage III-IV and Stage V (p > 0.05).

Table 3 BMD T-scores among the studied groups
Full size table

Table 4 shows a significant increase of creatinine, phosphorus, alkaline phosphatase, 8-OHdG, MDA, and PTH in total CKD patients compared to the control, while Vitamin D, Ca, albumin, and PON1 decreased. Regarding the values in these markers among the patients with different CKD stages, there were significant differences (p < 0.05), post hoc analysis revealed statistically significant difference in all the studied laboratory biomarkers among patients with stage I-II vs. cases with stage III-IV and stage V CKD (p < 0.05).

Table 4 Laboratory findings among the studied groups
Full size table

Our results revealed also a significant positive correlation between both MDA and 8-HdOG with alkaline phosphatase and phosphorus. However, they had a significant negative correlation with vitamin D and calcium. PON-1 was negatively correlated significantly with alkaline phosphatase, PTH & phosphorus, whereas, it positively correlated significantly with vitamin D and calcium. Moreover, there was a significant positive correlation between PON1and BMD as measured by T-scores of LS, DR and FN, meanwhile, 8-OHdG and MDA had a negative correlation with BMD as shown in Table 5.

Table 5 Correlation of OS biomarkers with BMD and biochemical findings in total CKD patients
Full size table

Table 6 shows stepwise multiple regression analysis of BMD T-scores of LS, FN and DR with OS in CKD patients. MDA, PON1, and 8-OHdG were included as independent variables while BMD T-scores as dependent variable. Significant association between each of MDA, 8-HdOG, and PON1 with T-scores was observed.

Table 6 Stepwise multiple regression analysis of BMD T-scores with OS markers in CKD patients
Full size table

Discussion

OS and acceleration of the inflammatory state are closely linked to the severity and course of CKD. Numerous investigations have documented decreased anti-oxidative systems and increased levels of pro-inflammatory enzymes, cytokines and OS indicators [36].

Several researches have proved that OS harmfully affects the process of bone remodeling, leading to decrease in BMD [37, 38]. Current documents showed that inflammation caused by OS plays a role in the etiology of OP [39]. Therefore, in this study; we intended to evaluate the association of BMD with OS in CKD.

In the current study, CKD patients with Stage1-2, Stage 3–4 and Stage 5 had lower T-scores for LS, DR and FN than the control group. Whereas, cases with Stage1-2 had higher T-scores as compared to Stage 3–4 and Stage 5. So, BMD had a significant negative association with the stage of CKD, which is coherent with prior researches that reported low BMD among stage 3–5 patients [40, 41].

Park et al., declared that reduction of BMD was prevalent in patients with end stage renal disease (Stage 5) and it was precipitating element to fracture; causing long-lasting inability in those patients [42]. This is in agreement with our results.

In end stage renal disease (ESRD) patients; excretion of phosphorus, diminished metabolism of vitamin D3, reduced calcium level, elevated PTH, chronic acidosis, old age, increased presence of diabetes as a causative factor and impaired nutritional intake are proposed to be reasons of bone illness [43, 44].

In the present study, we also observed a significant increase in alkaline phosphatase and PTH in CKD cases compared to the control group, while vitamin D levels were significantly decreased.

Agreeing with our results, Nickolas et al., proved that high levels of PTH were associated with low BMD [45]. Additionally, the association of this hormone with fracture was described mostly in patients on dialysis [46].

Moreover, it is a fact that elevated level of PTH expects damage of cortical area, density, thickness, and intensifies the porosity of cortical area, whereas it reduces the strength of bone, that creates OP [47]. Generally, increased 25(OH)D levels have a great effect on bone strength due to its active metabolite [1,25(OH)2D] action in intestines, parathyroid gland and bone [48, 49]. At clinical level, intake of precursors/analogues of vitamin D; ergocalciferol, cholecalciferol, and calcifediol were accompanied with decrease in PTH concentrations in CKD cases [50]. Therefore, administration of vitamin D significantly affects metabolism of bone and proper concentrations of vitamin D increases the effectiveness of anti-resorptive treatments, like; bisphosphonates [51].

Regarding the OS biomarkers in our study, we assessed MDA which is produced through lipid peroxidation and during prostaglandin and thromboxane synthesis and could attack big molecules, resulting in changes in their roles [52]. In many researches, greater serum MDA concentrations were shown in CKD cases than healthy controls [53, 54]. MDA differed significantly in CKD cases in stages 2, 3, 4, and 5 [55]. Higher levels of serum MDA were also found in haemodialysis patients [56]. Furthermore, serum MDA decreased after kidney transplantation [57].

The above mentioned findings coincide with the results of our study as we found significant increase in MDA in total studied cases with CKD compared to the controls (p = 0.001). It is worth noting that MDA levels differed significantly according to the severity of CKD (p = 0.001) in the current study.

This agrees with the cross-sectional study done by Sagar et al., on four hundred individuals including three hundreds cases having CKD and one hundred normal subjects as a control. MDA levels were significantly different between groups. Stage V cases had the highest levels compared to the other groups [58].

8-hydroxy-2-deoxyguanosine (8-OHdG), one of the greatest profuse products of DNA oxidation, is a sensitive OS biomarker which reflects very small levels of oxidative DNA destruction [59]. High concentration of serum 8-OHdG acts as a surrogate biomarker of oxidative DNA damage in dialysis cases [60, 61]. An elevated level of 8-OHdG in leukocyte DNA was detected in peritoneal and haemodialysis cases. They had the highest 8-OHdG level, then un-dialyzed CKD patients and healthy controls [61].

In this regards, we assessed 8-OHdG in our CKD patients and detected that the above findings coincide with the results of our study as we found significant increase in serum 8-OHdG in total studied cases with CKD compared to the controls (p = 0.001). Furthermore, in our study, we noticed an association of 8-OHdG with the severity of CKD.

Concomitant with our results, Dai et al., found that Serum 8-hydroxydeoxyguanosine (8-OHdG) increased with worsening of kidney function [62].

From another aspect, the findings of the present work are parallel to that of a meta-analysis done by Watanabe et al., on twenty four researches and found that CKD individuals had a lesser level of PON-1 than the control; proving that the antioxidant function of PON1 can be reduced in CKD [63].

Furthermore, in our study, we noticed a decrease of antioxidant biomarker (PON-1) with a further decrease in renal function.

On evaluating PON1 activity as a prognostic and diagnostic tool in CKD, Samouilidou et al., noticed that PON1 activity may be utilized in the assessment of antioxidant status in both dialyzed and non-dialyzed patients, the prediction of CVD in patients undergoing dialysis and transplantation, the assessment of the antioxidant effect of statins and nutritional supplementation, the assessment of nephropathy occurrence in individuals with T2DM, and the prognosis of future adverse clinical outcomes [64].

It was found that redox regulation of bone remodeling acts at the molecular level. A lot of information showed that higher ROS levels were connected with an intensification in apoptosis of osteocytes and/or osteoblasts, accountable for the damaged balance of bone remodeling. Especially, at the molecular level, in vitro researches proved that elevated ROS levels linked to osteocyte apoptosis had mitochondrial basis, and that c-Jun-N terminal kinase (JNK) activation through mitochondrial pathways is the principal action [65, 66]. OS-stimulated apoptosis is the result of the activation of caspase-3, -6, and − 7, initiated by the production of cytochrome C through the external mitochondrial membrane, to increase its permeability [67].

Thiol antioxidants, like GSH, lipoic acid (LA), and N-acetylcysteine (NAC; a cysteine analogue drug with therapeutic uses), can decrease ROS release and apoptosis due to caspase-3 activation; especially, apoptosis is prohibited by the specific prevention of JNK stimulation [65]. Antioxidants can also prevent ROS increase, JNK activation, and osteocyte apoptosis via controlled redox and non-redox mechanisms [65, 66, 68].

On the other hand, MDA has a powerful toxic effect on the cells, polymerizing macromolecules (proteins, lipids and DNA & RNA), strongly reflecting the speed and severity of lipid peroxidation. It could be considered as an indirect indicator for intensity of injury caused by free radicals, representing the procedure of ROS injury. In addition, MDA is able to prevent the protein and nucleic acid formation and reduce the enzyme action, leading to reduced antioxidants in the body and so progressively decreasing the bone mass. After OS induces the osteoclast growth and differentiation, osteoclasts will yield additional ROS, aggravate the impairment of the antioxidant defense system in the body and lead to a vicious circle, eventually causing severe OP [69].

A study done by Ren et al., investigated the relationship between OS and OP among ESRD patients on maintenance hemodialysis and found significantly greater MDA levels in those patients than the controls, demonstrating that maintenance hemodialysis cases having OP suffered a state of evident OS [70]. Ren et al., concluded also that MDA levels were negatively correlated with BMD and Hemodialysis CRF patients were prone to OP, having a significant OS status; its degree was closely related to OP [70]. This is compatible with our results.

In contrast to the results of the current study, Kayabaşi et al., reported that TAC significantly correlated positively with T score of FN only, while they couldn’t find any significant correlation between other studied OS biomarkers and T-scores of FN or LS in ESRD patients. They detected high OS and reduced antioxidant capacity. However, they couldn’t detect that OS had any impact of on OP in ESRD patients [71]. This disagrees with our results.

The role of OS in pathogenesis of OP can be attributed also to the occurrence of oxidants-antioxidants imbalance that can prevent the maturation of osteoblast precursors to osteoblasts, preventing osteoblasts mineralization then enhancing their demise. When OS induces the osteoclasts to grow and get into maturation, osteoclasts subsequently form extra ROS, aggravating the destruction of the antioxidant defending process inside the body. This produces a vicious circle and eventually causes severe OP [69].

Our study has a major strength that we assessed the relation between OS and BMD in all stages of CKD while up to our knowledge; all the previuos studies investigated the relation of OS and OP in ESRD (Dialyzed patients) only.

Limitations of the study

Our study has some limitations; includig:

Firstly; the cross sectional design of our study which prevented us from follow up of patients with CKD until they develop the OP with regular measurement of OS biomarkers and administration of antioxidants to assess their effects in improving CKD and BMD and prevention of OP. Hence, further longitudinal follow up studies and clinical trials with greater number of patients are required to approve the results of the current study and endorse the usage of those OS biomarkers as indicators of CKD prognosis. Furthermore, prospective researches targeting possible dietary interferences to reduce OS and bone resorption in individuals with chronic renal disease are very essential.

Secondly, we measured only three biomarkers of OS which is not enough in assessment of OS status as the evaluation comprises a battery of investigations including; oxidants, antioxidant enzymes, elements and vitamins but we couldn’t do this as it would cost us too much and our study didn’t receive any fund; it was self funded.

Thirdly, the current research did not intervene with or assess the lifestyle effects in CKD individuals (nutritional status, dietary habits and physical activity) and additional risk factors which also contribute to OS and decrease BMD.

Fourthly, we didn’t investigate the CKD patients according to the cause of CKD and its relation to OS and BMD.

Conclusions

The present study demonstrates that patients with CKD have low BMD being the lowest in stages 3–4 and 5, thus more predisposed to OP with a negative association between BMD and CKD severity. CKD patients suffer of OS. There is a negative association between OS and BMD. OS might participate in the occurrence of OP in CKD.

Data availability

The study Data are available upon request from the corresponding author.

Abbreviations

Alp:

Alkaline phosphate

aOR:

adjusted odd ratio

BMD:

Bone mineral density

Ca:

Calcium

CKD:

Chronic kidney disease

DEXA:

Dual energy x-ray absorptiometry

DR:

Distal radius

e-GFR:

estimated glomerular filtration rate

ESRD:

End stage renal disease

FN:

Femur neck

GFR:

Glomerular filtration rate

KIDGO:

Kidney Disease Improving Global Outcomes

LS:

Lumbar spine

MBD:

Mineral bone disorder

MDA:

Malondialdehyde

NHANES:

National Health and Nutrition Examination Survey

OHdG:

8-Hydroxy-2’-deoxyguanosine

OP:

Osteoporosis

OPG:

Osteoprotegerin

OS:

Oxidative stress

PTH:

Parathyroid hormones

PON1:

Paraoxonase1

RANKLE:

Of receptor activator of nuclear factor-κb ligand

ROS:

Reactive oxidative species

SMD:

Standard mean difference

SOD:

Superoxide dismutase

TAC:

Total antioxidant capacity

TBARS:

Thiobarbituric acid reactive substances

References

  1. Francis A, Harhay MN, Ong A, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473–85. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/s41581-024-00820-6.

    Article  PubMed  Google Scholar 

  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117–314.

  3. Pimentel A, Ureña-Torres P, Bover J, Luis Fernandez-Martín J, Cohen-Solal M. Bone fragility fractures in CKD patients. Calcif Tissue Int. 2021;108:539–50.

    Article  CAS  PubMed  Google Scholar 

  4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group KDIGO. 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.kisu.2017.04.001.

    Article  Google Scholar 

  5. Chao C-T, Wang J, Huang J-W, Chan D-C, Hung K-Y, Chien K-L, et al. Chronic kidney disease–related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score–matched cohort study. Osteoporos Int. 2020;31:699–708.

    Article  CAS  PubMed  Google Scholar 

  6. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the united States. J Am Soc Nephrol. 2006;17:3223–32.

    Article  PubMed  Google Scholar 

  8. Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13:962–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570–6.

    Article  CAS  PubMed  Google Scholar 

  10. Moe SM. Renal osteodystrophy or kidney-induced osteoporosis? Curr Osteoporos Rep. 2017;15:194–7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fukumoto S, Matsumoto T. Recent advances in the management of osteoporosis. F1000 Res. 2017;6:625. https://doiorg.publicaciones.saludcastillayleon.es/10.12688/f1000research.10682.1.

    Article  CAS  Google Scholar 

  12. -Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines committee of the American college of physicians.treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American college of physicians. Ann Intern Med. 2017;166(11):818–39.

    Article  PubMed  Google Scholar 

  13. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277(06):650–61. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/joim.12369.

    Article  CAS  PubMed  Google Scholar 

  14. (https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/musculoskeletal/en/05_Moduleonosteoporosis/01_Module_on_Osteo_chapter1.pdf).

  15. Sies H. Oxidative stress: concept and some practical aspects. Antioxidants. 2020;9:852.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. JBJS. 2021;103:1451–61.

    Article  Google Scholar 

  17. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology. 2012;17:311–21.

    Article  CAS  PubMed  Google Scholar 

  18. Parascandolo A, Laukkanen MO. Carcinogenesis and reactive oxygen species signaling: interaction of the NADPH oxidase NOX1-5 and superoxide dismutase 1–3 signal transduction pathways. Antioxid Redox Signal. 2019;30:443–86. [CrossRef].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981-90. [CrossRef] [PubMed].

  20. Hong SE, Lee J, Seo DH, Lee H, Park DR, Lee GR, Jo YJ, Kim N, Kwon M, Shon H, et al. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclasts. Free Radic Biol Med. 2017;112:191-9.

  21. Tian X, Cong F, Guo H, Fan J, Chao G, Song T. Downregulation of Bach1 protects osteoblasts against hydrogen peroxide-induced oxidative damage in vitro by enhancing the activation of Nrf2/ARE signaling. Chem Biol Interact. 2019;309:108706. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.cbi.2019.06.019.

    Article  CAS  PubMed  Google Scholar 

  22. Gong W, Liu M, Zhang Q, et al. Orcinol glucoside improves senile osteoporosis through attenuating oxidative stress and autophagy of osteoclast via activating Nrf2/Keap1and mTOR signaling pathway. Oxidative Med Cell Longev. 2022;2022:5410377. https://doiorg.publicaciones.saludcastillayleon.es/10.1155/2022/5410377.

    Article  CAS  Google Scholar 

  23. Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Jt Surg. 2021;103:1451–61. [CrossRef].

    Article  Google Scholar 

  24. Hintze J, Kaysville LLC. Utah, USA. www.ncss.com.

  25. de Bezerra KS, Vasco RFV, Custodio MR, Jorgetti V, Moysés RMA, Elias RM. Chronic kidney disease is associated with low BMD at the hip but not at the spine. Osteoporos Int. 2019;30:1015–23.

    Article  Google Scholar 

  26. Levey AS, Levin A, Kellum JA. Definition and classification of kidney diseases. Am J Kidney Dis. 2013;61:686–8.

    Article  PubMed  Google Scholar 

  27. Hiernaux J, Tanner JM. Growth and physique: anthropometry. Hum Biol a Guid to F methods. Philadelphia, FA Davis Co. 1969; 2–42.

  28. Winzenberg T, Jones G. Dual energy X-ray absorptiometry. Aust Fam Physician. 2011;40(1/2):43–4.

    PubMed  Google Scholar 

  29. Izadyar S, Golbarg S, Takavar A, Zakariaee SS. The effect of the lumbar vertebral malpositioning on bone mineral density measurements of the lumbar spine by dual-energy X-ray absorptiometry. J Clin Densitom. 2016;19:277–81.

    Article  PubMed  Google Scholar 

  30. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. PMID: 7941614.

  31. Messina C, Maffi G, Vitale JA, Ulivieri FM, Guglielmi G, Sconfienza LM. Diagnostic imaging of osteoporosis and sarcopenia: a narrative review. Quant Imaging Med Surg. 2018;8(1):86–99.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Faulkner KG, Roberts LA, McClung MR. Discrepancies in normative data between Lunar and Hologic DXA systems. Osteoporos Int. 1996;6(6):432-6. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/BF01629574. PMID: 9116387.

  33. Sheu A, Diamond T. Secondary osteoporosis. Aust Prescr. 2016;39:85.

    PubMed  PubMed Central  Google Scholar 

  34. Nair V, Turner GA. The thiobarbituric acid test for lipid peroxidation: structure of the adduct with malondialdehyde. Lipids. 1984;19:804–5.

    Article  CAS  Google Scholar 

  35. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1. 1.2) based upon Inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem. 1992.

  36. Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci. 2019;21:263.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Savasky BM, Mascotti DP, Patel N, Rodriguez-Collazo E. Nutritional and Pharmacological effects on oxidative stress in soft tissue and bone remodeling. J Nutr Metab. 2018;2018:4183407. https://doiorg.publicaciones.saludcastillayleon.es/10.1155/2018/4183407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ohyama Y, Ito J, Kitano VJ, Shimada J, Hakeda Y. The polymethoxy flavonoid Sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors. PLoS ONE. 2018;13:e0191192. https://doiorg.publicaciones.saludcastillayleon.es/10.1371/journal.pone.0191192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mohamad N-V, Ima-Nirwana S, Chin K-Y. Are oxidative stress and inflammation mediators of bone loss due to Estrogen deficiency? A review of current evidence. Endocr Metab Immune Disord Drug Targets. 2020;20:1478–87. https://doiorg.publicaciones.saludcastillayleon.es/10.2174/1871530320666200604160614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the rancho Bernardo study. J Bone Min Res. 2007;22:203–10.

    Article  CAS  Google Scholar 

  41. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.

    Article  CAS  PubMed  Google Scholar 

  42. Park S-H, Jia T, Qureshi AR, Bárány P, Heimbürger O, Larsson TE, et al. Determinants and survival implications of low bone mineral density in end-stage renal disease patients. J Nephrol. 2013;26:485–94.

    Article  CAS  PubMed  Google Scholar 

  43. Langote A, Ahearn M, Zimmerman D. Dialysate calcium concentration, mineral metabolism disorders, and cardiovascular disease: deciding the Hemodialysis bath. Am J Kidney Dis. 2015;66:348–58.

    Article  CAS  PubMed  Google Scholar 

  44. Gal-Moscovici A, Sprague SM, Endocrinology, Dialysis Jean L, Holley. Series editor: osteoporosis and chronic kidney disease. Seminars in Dialysis. Wiley Online Library; 2007. pp. 423–30.

  45. Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol. 2011;22:1560–72.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study. Nephrol Dial Transpl. 2012;27:345–51.

    Article  CAS  Google Scholar 

  47. Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Min Res. 2013;28:1811–20.

    Article  CAS  Google Scholar 

  48. Cavalier E, Makris K, Heijboer AC, Herrmann M, Souberbielle J-C. Vitamin D: analytical advances, clinical impact, and ongoing debates on health perspectives. Clin Chem. 2024;3(9):1104–21. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/clinchem/hvae056.

    Article  Google Scholar 

  49. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.

    Article  CAS  PubMed  Google Scholar 

  50. Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, et al. Use of extended-release Calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44:316–25.

    Article  CAS  PubMed  Google Scholar 

  51. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6:50–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bigagli M, Lodovici M. Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications. Oxid Med Cell Longev. 2019;2019:5953685. https://doiorg.publicaciones.saludcastillayleon.es/10.1155/2019/5953685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, Atamer Y. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol. 2008;21:924–30.

    CAS  PubMed  Google Scholar 

  54. De Vecchi AF, Bamonti F, Novembrino C, Ippolito S, Guerra L, Lonati S, Salini S, Aman CS, Scurati ME, Cighetti G. Free and total plasma malondialdehyde in chronic renal insufficiency and in Dialysis patients. Nephrol Dial Transpl. 2009;24:2524–9. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/ndt/gfp102.

    Article  CAS  Google Scholar 

  55. Kirkman HN, Rolfo M, Ferraris AM, Gaetani GF. Mechanisms of protection of catalase by NADPH. Kinetics and stoichiometry. J Biol Chem. 1999;274:13908–14. https://doiorg.publicaciones.saludcastillayleon.es/10.1074/jbc.274.20.13908.

    Article  CAS  PubMed  Google Scholar 

  56. Kaya Y, Ari E, Demir H, Soylemez N, Cebi A, Alp H, Bakan E, Gecit I, Asicioglu E, Beytur A. Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with oxidative DNA damage. Nephrol Dial Transpl. 2012;27:1164–9. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/ndt/gfr443.

    Article  CAS  Google Scholar 

  57. Zahmatkesh M, Kadkhodaee M, Mahdavi-Mazdeh M, Ghaznavi R, Hemati M, Seifi B, Golab F, Hasani K, Lessan PM, Einollahi B. Oxidative stress status in renal transplant recipients. Exp Clin Transpl. 2010;8:38–44.

    Google Scholar 

  58. Sagar P, Pranay K, Shekhar R, Singh PP, Kumar P. Serum malondialdehyde in different stages of chronic renal disorder. Asian J Med Sci. 2023;14:113–8.

    Article  Google Scholar 

  59. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Research/Reviews Mutat Res. 1997;387(3):147–63. ISSN 1383 -5742. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/S1383-5742(97)00035-5.

    Article  CAS  Google Scholar 

  60. Tarng DC, Wen Chen T, Huang TP, Chen CL, Liu TY, Wei YH. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal Dialysis patients. J Am Soc Nephrol. 2002;13:1321–30. https://doiorg.publicaciones.saludcastillayleon.es/10.1097/01.ASN.0000013301.11876.7E.

    Article  CAS  PubMed  Google Scholar 

  61. Tarng DC, Huang TP, Wei YH, Liu TY, Chen HW, Wen Chen T, Yang WC. 8-hydroxy-2′-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic Hemodialysis patients. Am J Kidney Dis. 2000;36:934–44. https://doiorg.publicaciones.saludcastillayleon.es/10.1053/ajkd.2000.19086.

    Article  CAS  PubMed  Google Scholar 

  62. Dai L, Watanabe M, Qureshi AR, Mukai H, Machowska A, Heimbürger O, et al. Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. Eur J Intern Med. 2019;68:60–5. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.ejim.2019.07.035.

    Article  CAS  PubMed  Google Scholar 

  63. Watanabe J, Kotani K, Gugliucci A. Paraoxonase 1 and chronic kidney disease: a meta-analysis. J Clin Med. 2023;12:1199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Samouilidou EC, Liaouri A, Kostopoulos V, Nikas D, Grapsa E. The importance of paraoxonase 1 activity in chronic kidney disease. Ren Fail. 2024;46(2):2376930. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/0886022X.2024.2376930.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Fontani F, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT, Glutathione N-A. Lipoic acid Down-Regulate Starvation-Induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling. Calcif Tissue Int. 2015;96:335–46. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00223-015-9961-0.

    Article  CAS  PubMed  Google Scholar 

  66. Domazetovic V, Fontani F, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT. Estrogen inhibits Starvation-Induced apoptosis in osteocytes by a Redox-Independent process involving association of JNK and glutathione S-Transferase P1-1. FEBS Open Bio. 2017;7:705–18. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/2211-5463.12216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Jilka RL, Noble B, Weinstein RS. Osteocyte Apoptosis Bone. 2013;54:264–71. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.bone.2012.11.038.

  68. Domazetovic V, Marcucci G, Pierucci F, Bruno G, Di Cesare Mannelli L, Ghelardini C, Brandi ML, Iantomasi T, Meacci E, Vincenzini MT. Blueberry juice protects osteocytes and bone precursor cells against oxidative stress partly through SIRT 1. FEBS Open Bio. 2019;9:1082–96. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/2211-5463.12634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Nurdiana N, Mariati N, Noorhamdani N, Setiawan B, Budhiparama N, Noor Z. Effects of labisia Pumila, on oxidative stress in rat model of post-menopausal osteoporosis. Asian Pac J Reprod. 2016;5:391–4.

    Article  Google Scholar 

  70. Ren H, Sun R, Wang J. Relationship of melatonin level, oxidative stress and inflammatory status with osteoporosis in maintenance Hemodialysis of chronic renal failure. Exp Ther Med. 2018;15:5183–8.

    PubMed  PubMed Central  Google Scholar 

  71. Kayabaşı H, Şit D, Kadiroğlu AK, Yılmaz ME. The relationship between oxidative stress and osteoporosis in chronic Dialysis patients. Nefroloji Hemşireliği Derg. 2023;18:99–103.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

The study as not funded by any agent.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt

    Samah M. Akab & Hanaa Elsayed Abozeid

  2. Department of Rheumatology and Rehabilitation, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt

    Seham A. Elazab

  3. Health Insurance, Nasr City, Egypt

    Sherien Abdallh Fathy Elazab

  4. Department of Internal Medicine, Faculty of Medicine, Banha University, Banha, Egypt

    Noran ElBazzar

  5. Department of Medical Biochemistry, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt

    Eman Refaat Youness, Mohamed Ahmed Shahba & Hisham A. Orban

  6. Biological Anthropology Department, Medical Research and Clinical Studies, Institute– National Research Centre, Cairo, Egypt

    Hanaa Reyad Abdallah & Moushira Zaki

Authors
  1. Samah M. Akab
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Hanaa Elsayed Abozeid
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Seham A. Elazab
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Sherien Abdallh Fathy Elazab
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Noran ElBazzar
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Eman Refaat Youness
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Mohamed Ahmed Shahba
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Hisham A. Orban
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Hanaa Reyad Abdallah
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Moushira Zaki
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

SMA conceptualization, design of the study, clinical assessment of cases and data collection. HEA clinical assessment of cases and data collection. SAE conceptualization, design of the study, clinical assessment of cases, data collection and performing DEXA. SAFE clinical assessment of cases and collection of data. NE Clinical assessment and data collection. ERY resources and laboratory investigations. MAS resources and laboratory investigations. HAO resources and laboratory investigations. HRA clinical and anthropometric assessment of cases, reviewing and editing the final manuscript. MZ statistical analysis and interpretation of data, writing the manuscript. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Hanaa Reyad Abdallah.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethical Committee of Al-Azhar University (No. 1758) according to the World Medical Association’s Declaration of Helsinki. Written informed consent was obtained from patients after explaining the study for them.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akab, S.M., Abozeid, H.E., Elazab, S.A. et al. Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study. BMC Nephrol 26, 197 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12882-025-04099-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12882-025-04099-y

Keywords

BMC Nephrology

ISSN: 1471-2369

Contact us